Pars Plana Vitrectomy for Diabetic Fibrovascular Proliferation With and Without Internal Limiting Membrane Peeling
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Internal limiting membrane peeling in diabetic vitrectomy will help prevent postoperative epiretinal membrane formation
| Condition | Intervention | Phase |
|---|---|---|
|
Patients With Proliferative Diabetic Retinopathy Who Have Active Fibrovascular Proliferation |
Procedure: ILM peeling |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Single Blind (Investigator) Primary Purpose: Treatment |
| Official Title: | Pars Plana Vitrectomy for Diabetic Fibrovascular Proliferation With and Without Internal Limiting Membrane Peeling |
- Snellen BCVA and epiretinal membrane formation measured with OCT [ Time Frame: within 6 months after the surgery ]
- central macular thickness measured bt OCT [ Time Frame: within 6 months after the surgery ]
| Estimated Enrollment: | 40 |
| Study Start Date: | April 2007 |
| Estimated Study Completion Date: | November 2007 |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: 2 |
Procedure: ILM peeling
ILM maculorhexis is initiated using scraper and completed using a 25-gauge Synergetics (St. Louis, MO) forceps.
|
Detailed Description:
Progressive fibrovascular proliferation may occur despite appropriate panretinal photocoagulation in diabetic patients. Fibrovascular proliferation may lead to persistent or recurrent vitreous hemorrhage, macular traction, or traction macular detachment, and becomes a major indication for vitrectomy.1 During the past 25 years, anatomical and visual results of vitrectomy for severe proliferative diabetic retinopathy have improved as a result of improved understanding of the pathoanatomy and improvements in surgical instrumentation.2-5 Although anatomical success is high after complete vitrectomy, recurrent epiretinal membrane may cause macular thickening, cysts formation, preventing good functional outcome.6 An epiretinal membrane (ERM) is a non-vascular cellular membrane that may cause symptomatic visual disturbances due to retinal wrinkling and distortion.7 These epiretinal membranes have been found to be composed of fibroblasts, glial cells, macrophages, myofiboblasts, nad retinal pigment epithelial cells.8-9 Studies have suggested removal of internal limiting membrane (ILM) may decrease the likelihood of post-operative ERM formation in cases of diabetic macular edema and idiopathic ERM. It is postulated that removal of the ILM removes the scaffold upon which myofibroblasts would proliferate.10 Efficacy of vitrectomy including removal of ILM was mostly described as facilitating resolution of diffuse diabetic macular edema11 and improvement of visual acuity or in macular hole surgery in diabetic patients.12However, it is unknown if removal of ILM during vitreoretinal surgery in diabetic patients with active fibrovascular proliferation is useful in preventing postoperative ERM formation. The purpose of this study is to compare the postoperative epiretinal membrane (ERM) formation and visual outcome in diabetic patients with active fibrovascular proliferation who underwent vitrectomy with or without ILM peeling.
Eligibility| Ages Eligible for Study: | 30 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- active fibrovascular proliferation with or without tractional detachment
- previous pan-retinal photocoagulation at least 3 months before
Exclusion Criteria:
- biomicroscopic evidence of macular hole
- combination of tractional and rhegmatogenous retinal detachment
- location of fibrovascular proliferation anterior to the equator
- major ocular surgery history(including, scleral buckle, glaucoma filter, cornea transplant, vitreoretinal surgery etc
- the presence of other ocular conditions such as glaucoma, uveitis, or other ocular inflammatory diseases.
Contacts and Locations| Contact: Pei-yao Chang, M.D. | 886-2-23123456 ext 5187 | peiyao@seed.net.tw |
| Taiwan | |
| National Taiwan University Hospital | Recruiting |
| Taipei, Taiwan | |
| Contact: Chung-may Yang, M.D. 886-2-23123456 ext 5187 peiyao@seed.net.tw | |
| Principal Investigator: | Chung-may Yang, M.D. | National Taiwan University Hospital |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00556244 History of Changes |
| Other Study ID Numbers: | 200704053M |
| Study First Received: | November 8, 2007 |
| Last Updated: | November 8, 2007 |
| Health Authority: | Taiwan: Department of Health |
Additional relevant MeSH terms:
|
Diabetic Retinopathy Retinal Diseases Eye Diseases Diabetic Angiopathies Vascular Diseases |
Cardiovascular Diseases Diabetes Complications Diabetes Mellitus Endocrine System Diseases |
ClinicalTrials.gov processed this record on May 19, 2013